The Copaxone News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
March 2005   
June 2005   
July 2005   
August 2005   
October 2005   
November 2005   
December 2005   
January 2006   
February 2006   
May 2006   
June 2006   
August 2006   
October 2006   
November 2006   
December 2008   
January 2013   
May 2013   
June 2013   
July 2013   
September 2013   
October 2013   
November 2013   
November 2014   
December 2014   
January 2015   
March 2015   
April 2015   
May 2015   
July 2015   
February 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Mylan Confirms Continued Patent Proceedings Concerning MS Therapy Copaxone


According to a press release from Mylan N.V., the U.S. Patent and Trademark Office (PTO) has issued an inter partes review (IPR) proceeding on all claims against a third Copaxone patent for the 40 mg/mL (U.S. Patent No. 8,969,302) formulation by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. The news represents continued patent challenges and efforts by other pharmaceutical companies to produce generic forms of Copaxone, which is a leading multiple sclerosis therapy for the relapsing-remitting form of the disease.

Copaxone is delivered via subcutaneous injection and has been found to be effective for many patients with RRMS in mitigating the number and severity of relapses. Multiple Sclerosis occurs when the nerve cells present a different morphology, namely, when the insulating covers of myelin around the cells and spinal cord are damaged, leading to the disruption of the ability of communication among the different parts of the nervous system. Due to this atypical morphology, the immune system identifies those cells as a potential target to eliminate by releasing biological markers, attacking the central nervous system (CNS), which includes brain, spinal cord and optic nerves. All in all, MS results from an immune-mediated process. While there are different forms of the disease, the relapsing-remitting form is the most common, making therapies such as Copaxone widely prescribed to control such exacerbations.

Copaxone is composed of Glatiramer Acetate (GA) , a polymer with immune response regulation properties. Once in the body, the GA polymer competes against the biological markers to bind to the myelin fibers. In this way, the immune reaction against the CNS becomes less intense.

Last year, the U.S. Food and Drug Administration (FDA) accepted a new drug application (ANDA) filing for three-times-per-week Glatiramer Acetate Injection 40 mg/mL, developed by Mylan, a generic version of Copaxone 40 mg/mL. Mylan believes that their generic version of the drug shows promise for being granted 180 days of marketing exclusivity in the US after FDA approval. The expiration of the original Teva patent for Copaxone has spurred on patent challenges and legal action as drug manufacturers move to offer generic versions of the therapy.

In this latest development, the PTO has instituted IPR proceedings against two related Copaxone® 40 mg/mL patents, the U.S. Patent Nos. 8,232,250 and 8,399,413 on all claims, and the oral hearing will take place in May 2016.

Mylan is one of the world’s leading generic and specialty pharmaceutical company, with its headquarters in the United Kingdom. It has around 1,400 products in its portfolio.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length